Drug makers of Tygacil are warned by FDA because of its high risks
Written By: Rheingold, Valet, Rheingold, Ruffo & Giuffra LLP
By Lisa S. Cummings
Are you familiar with the drug Tygacil? As a litigation firm who handles drug injury cases and infection-related medical malpractice cases, we wanted to bring you urgent news.
On Friday, Pfizer Inc's antibacterial drug Tygcil was found by the FDA to carry a Black Box warning for a higher risk of death than other drugs that are used to treat infection. The agency says that the increase of risk of death is has often been seen in patients who suffer hospital-acquired pneumonia.
The drug is approved to treat community acquired bacterial pneumonia as well as complicated skin and abdominal infections. Tygcil is recommended to be used when alternative treatments fail, so it is not popularly used. The upgraded warning will be inside a black box on the drug's label as well as in the "Warnings and Precautions" area of its label.
Since the issuing of the 2010 notice, there have been 10 trials analyzed by the FDA, using its data from patients who has taken the drug. Our law firm wants to help raise the awareness of this drug's serious risks or complications, so please contact us if you or a loved one has experienced complications from infections after using this drug.